

# HEMATOLOGIC MALIGNANCIES

Rimini Hotel Savoia | October 2019 | 17<sup>th</sup> - 18<sup>th</sup>

October 17<sup>th</sup>

## Chronic Lymphocytic Leukemia Chair: A. Lucchesi, A. Merli

09:00 Pathogenesis: Genes and microenvironment **D. Rossi**

09:30 Predictive biomarkers **A. Cuneo**

10:00 Bruton Tyrosin kinases inhibitors **JR Brown**

10:30 Coffe break

11:00 What's the role of Pi3 K inhibition? **L. Scarfò**

11:30 Bcl2 Inhibition **M. Montillo**

12:00 The best sequence of therapy in CLL in the era of novel agents **JR Brown**

## Aggressive Lymphomas Chair: G. Musuraca, M. Tani

12:30 Diagnostics, molecular advances and new targets in treating aggressive lymphomas **S. Pileri**

13:00 How I treat DLBCL in 2019 **G. Musuraca**

13:30 Lunch

14:30 Mantle cell lymphoma: The new treatment algorithm **S. Rule**

15:00 Primary CNS Lymphoma: Diagnosis and treatment **A. Ferreri**

15:30 T cell lymphomas **F. Zaja**

16:00 CAR T Cell and or Transplant in DLBCL **P. Corradini**

## Indolent Lymphomas Chair: E. Zuffa, S. Tomassetti

16:40 Marginal zone lymphomas **E. Zucca**

17:10 Waldenstrom macroglobulinemia: All about that **E. Kastritis**

17:40 Follicular lymphoma: Treatment algorithm and new drugs **F. Morschauer**

October 18<sup>th</sup>

## Acute Lymphoblastic Leukemia Chair: E. Zuffa, S. Tomassetti

08:30 Pathogenesis and treatment algorithm in Adult acute lymphoblastic leukemia **R. Bassan**

09:10 Salvage therapy and MRD **F. Lanza**

09:40 Ph+ and Ph like ALL: From Biology to treatment **O. Ottmann**

10:10 Coffee break

## Acute Myeloid Leukemia Chair: F. Lanza, G. Martinelli

10:45 Genetic of AML **B. Falini**

11:15 Risk adapted strategies in AML **G. Martinelli**

11:45 Role of the IDH1 and IDH 2 mutations **L. Bullinger**

12:05 FLT3 inhibition in AML **C. Papayannidis**

12:25 The long awaited Return of Mylotarg in AML **A. Venditti**

12:45 The revolution of bcl-2 inhibition...when and how **G. Saglio**

13:05 Lunch

14:10 Older patients with AML **F. Ferrara**

14:40 New techniques and considerations for the role of transplantation in AML **A. Nagler**

## Multiple Myeloma Chair: P. Tosi, C. Cerchione

15:10 Molecular Biology in Myeloma **C. Terragna**

15:30 Risk factors and criteria for treatment **F. Gay**

15:50 First line treatments in transplantable patients **E. Zamagni**

16:20 Strategies for transplant-ineligible patients and relapsed/refractory patients:  
The right sequence of treatment and new combinations **SK Kumar**

17:00 CAR T cells in Myeloma **P. Tosi**

17:30 Closing remarks

